Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $92

Benzinga Newsdesk www.benzinga.com Positive 82.5%

Neg 0% Neu 0% Pos 82.5%

Stifel analyst Alex Thompson maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $70 to $92.